Blume Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Blume Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$145	Hold	83	–	–	﹤0.01%	329
2025 Q4	$145	Hold	83	–	–	﹤0.01%	325
2025 Q3	$195	Hold	83	–	–	﹤0.01%	345
2025 Q2	$169	Hold	83	–	–	﹤0.01%	421
2025 Q1	$136	Hold	83	–	–	﹤0.01%	445
2024 Q4	$152	Hold	83	–	–	﹤0.01%	320
2024 Q3	$480	Hold	83	–	–	﹤0.01%	344
2024 Q2	$671	Hold	83	–	–	﹤0.01%	306
2024 Q1	$1.15K	Hold	83	–	–	﹤0.01%	297
2023 Q4	$510	Hold	83	–	–	﹤0.01%	306
2023 Q3	$389	Hold	83	–	–	﹤0.01%	307
2023 Q2	$447	Hold	83	–	–	﹤0.01%	311
2023 Q1	$820	Hold	83	–	–	﹤0.01%	295
2022 Q4	$1.56K	Hold	83	–	–	﹤0.01%	297
2022 Q3	$2K	Hold	83	–	–	﹤0.01%	294
2022 Q2	$2K	Hold	83	–	–	﹤0.01%	296
2022 Q1	$4K	Hold	83	–	–	﹤0.01%	293
2021 Q4	$5K	Hold	83	–	–	﹤0.01%	277
2021 Q3	$7K	Hold	83	–	–	﹤0.01%	268
2021 Q2	$9K	Hold	83	–	–	﹤0.01%	245
2021 Q1	$9K	Hold	83	–	–	﹤0.01%	225
2020 Q4	$9K	Hold	83	–	–	﹤0.01%	191
2020 Q3	$12K	Hold	83	–	–	0.01%	172
2020 Q2	$27K	Hold	83	–	–	0.02%	137
2020 Q1	$7K	Hold	83	–	–	﹤0.01%	193
2019 Q4	$3K	Hold	83	–	–	﹤0.01%	219
2019 Q3	$2K	Hold	83	–	–	﹤0.01%	222
2019 Q2	$3K	Hold	83	–	–	﹤0.01%	205
2019 Q1	$4K	Hold	83	–	–	﹤0.01%	211
2018 Q4	$4K	Hold	83	–	–	﹤0.01%	206
2018 Q3	$6K	Hold	83	–	–	﹤0.01%	176
2018 Q2	$4K	Hold	83	–	–	﹤0.01%	178
2018 Q1	$4K	Hold	83	–	–	﹤0.01%	192
2017 Q4	$4K	Hold	83	–	–	﹤0.01%	209
2017 Q3	$6K	Hold	83	–	–	﹤0.01%	208
2017 Q2	$8K	Hold	83	–	–	﹤0.01%	167
2017 Q1	$7K	Hold	83	–	–	﹤0.01%	164
2016 Q4	$7K	Hold	83	–	–	﹤0.01%	174
2016 Q3	$9K	Buy	+83	New	+$9.17K	0.01%	156

Other funds holding INO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Blume Capital Management's INO Position: Q1 2026 in Review

Blume Capital Management held its Inovio Pharmaceuticals (INO) position steady in Q1 2026 at 83 shares worth $145. The position accounts for ﹤0.01% of the portfolio, ranked #329.

Blume Capital Management first reported a position in INO in Q3 2016 and has held it in 39 quarters since. The position peaked at $27K in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

Blume Capital Management held 83 shares of Inovio Pharmaceuticals worth $145 as of Q1 2026.
Blume Capital Management left its Inovio Pharmaceuticals share count unchanged in Q1 2026.
Inovio Pharmaceuticals made up ﹤0.01% of Blume Capital Management's portfolio in Q1 2026, its #329 holding.
Blume Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2016 and has held it in 39 quarters since.
Blume Capital Management's Inovio Pharmaceuticals position peaked at $27K in Q2 2020.
100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Blume Capital Management's 13F filing for Q1 2026, filed 1 May 2026.